menu toggle

Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era

By Xcenda

Xcenda joined more than 5,000 attendees from around the world at ISPOR Europe 2019 in Copenhagen, Denmark and presented an educational symposium on Tuesday, November 5, 2019. Jay Jackson, Sr. Vice President of Consulting Services, and Dr. Thomas Mittendorf, Managing Director of Xcenda GmbH, along with industry leaders in France, Italy, and UK discussed and presented insights around value assessment and risk-sharing for new and innovative curative therapies.
Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era
Gene therapy, ATMPs (advanced therapy medicinal products), or personalized medicine—all these buzz words are now part of the day-to-day reality in our industry. With several recent regulatory approvals across the globe, discussion has ensued in earnest on how to assess their value and whether traditional reimbursement systems and health economic methods are fit-for-purpose to meet the unique challenges being encountered. These challenges center less on whether the innovations provide value, and more on affordability in our current short-term global financing systems.
 
To date, manufacturers have proactively addressed these topics with payers in various markets through pay-for-performance arrangements, milestone payments over various durations, and other novel payment schemes. All these developments over the short- and mid-term will lead to significant changes in how health care systems assess innovations during Health Technology Assessment pathways. Further, they will impact how financing systems evolve, especially with respect to risk sharing on potential outcomes.

 

The symposium provided insights on how payers and manufacturers across a number of important markets are currently dealing with these challenges.

 
  • Moderator: Jay Jackson, PharmD, MPH
    Sr. Vice President, Consulting Services, Xcenda, LLC, Palm Harbor, FL, USA
  • Speaker: Christian Hill
    Chief Executive Officer, MAP BioPharma Limited, Cambridge, United Kingdom
  • Speaker: Stève Bénard, PharmD
    Managing Director, stève consultants, Lyon, France
  • Speaker: Paola Lanati
    Managing Director, MA Provider, Milan, Italy
  • Speaker: Dr. Thomas Mittendorf
    Managing Director, Xcenda GmbH, Hannover, Germany